Study to assess the tolerability and efficacy of AMG-145 monotherapy in patients with hypercholesterolemia

Update Il y a 4 ans
Reference: EUCTR2011-001544-30

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the effect of 12 weeks of subcutaneous AMG 145 every-2-weeks (Q2W) or every-4-weeks (Q4W), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) when used as monotherapy in hypercholesterolemic subjects with a 10 year Framingham risk score of 10% or less.


Inclusion criteria

  • Hypercholesterolaemia

Links